Please wait while the formulary information is being retrieved.
ZYNLONTA (loncastuximab tesirine-lpyl)
- progressive diffuse large B-cell lymphoma
10 mg intravenous solution
- Infuse 0.075 mg/kg over 30 minute(s) by intravenous route on day 1 ofa 21 day cycle (cycles 3 and beyond)
Default screening record
- Infuse 0.15 mg/kg over 30 minute(s) by intravenous route on day 1 of a 21 day cycle (cycles 1 and 2)
- Infuse 0.075 mg/kg over 30 minute(s) by intravenous route on day 1 ofa 21 day cycle (cycles 3 and beyond)
- Infuse 0.0375 mg/kg over 30 minute(s) by intravenous route on day 1 of a 21 day cycle
- natalizumab
- Tysabri
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactation
Contraindicated
- Anemia
- Neutropenic disorder
- Pregnancy
- Severe infection
- Thrombocytopenic disorder
Severe
Moderate
- Child-pugh class A hepatic impairment
ZYNLONTA (loncastuximab tesirine-lpyl)
- progressive diffuse large B-cell lymphoma
- Abnormal hepatic function tests
- Anemia
- Exfoliative dermatitis
- Neutropenic disorder
- Thrombocytopenic disorder
- Edema
- Erythema
- Fatigue
- Hyperglycemia
- Hypoalbuminemia
- Maculopapular rash
- Musculoskeletal pain
- Nausea
- Peripheral edema
- Skin rash
More Frequent
Severe
Less Severe
- Infection
- Interstitial pneumonitis
- Pericarditis
- Pleural effusions
- Pleuritis
- Pneumonia
- Sepsis
- Acute abdominal pain
- Anorexia
- Constipation
- Diarrhea
- Dyspnea
- Pruritus of skin
- Skin photosensitivity
- Skin pigmentation enhancement
- Upper respiratory infection
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Extravasation injury
Less Severe
- Blistering skin
- Telangiectasia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Loncastuximab tesirine-lpyl
Safety and effectiveness not established in pediatric patients < 18 years.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatric patients < 18 years.
Loncastuximab Tesirine-lpyl
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Loncastuximab Tesirine-lpyl
Manufacturer does not rec during treatment and for 3 months after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Manufacturer does not rec during treatment and for 3 months after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Progressive diffuse large b-cell lymphoma | |
| C83.3 | Diffuse large b-cell lymphoma |
| C83.30 | Diffuse large b-cell lymphoma, unspecified site |
| C83.31 | Diffuse large b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.32 | Diffuse large b-cell lymphoma, intrathoracic lymph nodes |
| C83.33 | Diffuse large b-cell lymphoma, intra-abdominal lymph nodes |
| C83.34 | Diffuse large b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.35 | Diffuse large b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.36 | Diffuse large b-cell lymphoma, intrapelvic lymph nodes |
| C83.37 | Diffuse large b-cell lymphoma, spleen |
| C83.38 | Diffuse large b-cell lymphoma, lymph nodes of multiple sites |
| C83.39 | Diffuse large b-cell lymphoma, extranodal and solid organ sites |
| 0-9 | A-Z |
|---|---|
| C83.3 | Diffuse large b-cell lymphoma |
| C83.30 | Diffuse large b-cell lymphoma, unspecified site |
| C83.31 | Diffuse large b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.32 | Diffuse large b-cell lymphoma, intrathoracic lymph nodes |
| C83.33 | Diffuse large b-cell lymphoma, intra-abdominal lymph nodes |
| C83.34 | Diffuse large b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.35 | Diffuse large b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.36 | Diffuse large b-cell lymphoma, intrapelvic lymph nodes |
| C83.37 | Diffuse large b-cell lymphoma, spleen |
| C83.38 | Diffuse large b-cell lymphoma, lymph nodes of multiple sites |
| C83.39 | Diffuse large b-cell lymphoma, extranodal and solid organ sites |
Formulary Reference Tool